This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / IGC Pharma CALMA Trial Enrollment Nears
Business clinical trial

IGC Pharma CALMA Trial Enrollment Nears

Analysis based on 6 articles · First reported Apr 28, 2026 · Last updated Apr 28, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of IGC Pharma's Phase 2 CALMA trial nearing enrollment completion, coupled with its outreach efforts, could positively impact investor sentiment for IGC Pharma, as it signals progress in its drug development pipeline. Increased awareness of Alzheimer's agitation may also broaden the potential market for IGC Pharma's therapeutic candidates.

Biotechnology Pharmaceuticals
Event Summary

IGC Pharma, a clinical-stage biotechnology company, announced its participation in the caregiver-focused podcast Autumn Is Here. This initiative is part of a broader effort to increase awareness of agitation associated with Alzheimer's disease and support patient engagement in its ongoing Phase 2 CALMA clinical trial. The CALMA trial has reached approximately 80% patient enrollment and is advancing toward completion. Margarita Venegas and Barbara Forero from IGC Pharma were featured on the podcast, discussing the recognition and impact of agitation in Alzheimer's disease. Ram Mukunda, CEO of IGC Pharma, highlighted the importance of caregiver engagement in advancing Alzheimer's research. The company believes that caregiver education can support earlier symptom recognition and improve engagement in clinical studies.

Entities Involved
stock
IGC Pharma
IGC Pharma announced its participation in a caregiver-focused podcast to raise awareness for Alzheimer's disease agitation and support patient engagement in its Phase 2 CALMA clinical trial, which is nearing completion of enrollment. This outreach aims to accelerate the trial's progress and potential future drug development.
Importance 100.0 Sentiment 20.0
per
Ram Mukunda
Ram Mukunda, CEO of IGC Pharma, emphasized the importance of engaging with caregivers to advance Alzheimer's research and support the CALMA trial's progress.
Importance 70.0 Sentiment 20.0
per
Margarita Venegas
Margarita Venegas, Psychometric Training Manager at IGC Pharma, participated in the Autumn Is Here podcast to discuss recognizing agitation in Alzheimer's disease.
Importance 40.0 Sentiment 10.0
per
Barbara Forero
Barbara Forero, Clinical Neuropsychologist & Recruitment Coordinator at IGC Pharma, participated in the Autumn Is Here podcast to discuss recognizing agitation in Alzheimer's disease.
Importance 40.0 Sentiment 10.0
per
Francine Crawford
Francine Crawford hosted the Autumn Is Here podcast episode, providing a personal caregiving perspective to the discussion on Alzheimer's agitation.
Importance 20.0 Sentiment 0.0
oth
Autumn Is Here
Autumn Is Here is a caregiver-focused podcast that hosted IGC Pharma's representatives to discuss Alzheimer's disease agitation and the CALMA trial.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.